Molecular Pharming Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Crop Source (Maize, Barley, Tobacco, Safflower, Rice, Alfalfa), By Technology (Gene Gun, Agroinfiltration, Electroporation, Agrobacterium-Mediated Gene Transfer, Others), By Application (Recombinant Antibodies, Hormones, Vaccines, Industrial Enzymes, Proteins & Protein-Based Materials, Technical Reagents, Nutritional Products, Others), By End User (Biotechnology & Pharmaceutical Companies, Contract Manufacturing Organizations, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Molecular Pharming Market, valued at USD 2.56 Billion in 2024, is projected to experience a CAGR of 8.00% to reach USD 4.06 Billion by 2030. Molecular pharming involves the genetic engineering of plants, animals, or microorganisms to serve as bioreactors for producing pharmaceutical proteins, vaccines, and other valuable therapeutic compounds. The market's growth is primarily driven by the increasing demand for cost-effective biopharmaceuticals, coupled with continuous advancements in genetic engineering techniques that enhance production efficiency and yield. The inherent scalability and adaptability of molecular pharming platforms also contribute significantly to its expansion.

A notable challenge impeding market expansion is the complex regulatory landscape and the stringent approval processes governing genetically modified organisms and their derived products, along with concerns regarding potential environmental contamination risks. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), its member companies collectively invested nearly $101 billion in research and development in 2022, as indicated in their 2024 submission. This substantial investment in biopharmaceutical innovation broadly supports the technological advancements relevant to molecular pharming.

Key Market Drivers

The Global Molecular Pharming Market is significantly propelled by continuous advancements in genetic engineering technologies. These innovations enable increasingly precise and efficient modification of organisms for pharmaceutical protein production, fostering the development of novel therapeutic compounds and enhancing production yields. For instance, according to Labiotech. eu, September 30, 2025, "CRISPR technology's next wave: Ten companies to watch in 2025", Chroma, a company building an epigenetic editing platform, secured $135 million in Series B funding in 2023, highlighting substantial investment directed towards refining gene-editing capabilities that underpin molecular pharming applications. Such technological progress, including advanced gene-editing tools and synthetic biology techniques, is crucial for overcoming previous limitations in expression levels and product quality, thereby expanding the feasibility and commercial viability of molecular pharming systems across various platforms like plants and microbial hosts.

Concurrently, the increasing demand for biologics and therapeutic proteins acts as a powerful market driver, as molecular pharming offers a scalable and potentially more cost-effective alternative to traditional mammalian cell culture systems. The rising prevalence of chronic and infectious diseases necessitates a greater supply of complex biological drugs, and molecular pharming presents an avenue to meet this growing need. Evidencing this demand, according to PMC, September 2024, "Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023", 12 out of the 17 biologics approved by the FDA in 2023 were monoclonal antibodies, representing 70% of those approvals. The overall market also reflects strong financial support for the life sciences sector; according to the BioIndustry Association, July 14, 2025, "UK biotech attracts £1.23 billion in H1 2025", the UK's life sciences sector attracted £1.23 billion in venture capital investment in the first half of 2025, indicating robust confidence in innovative biopharmaceutical approaches including molecular pharming.

Download Free Sample Report

Key Market Challenges

A significant challenge impeding the growth of the Global Molecular Pharming Market is the complex regulatory landscape and the stringent approval processes governing genetically modified organisms and their derived products, along with concerns regarding potential environmental contamination risks. This intricate web of regulations directly impacts market expansion by extending the time required to bring novel biopharmaceuticals to market and increasing associated development costs.

The extensive testing, data collection, and sequential regulatory hurdles for genetically modified products, including those produced through molecular pharming, contribute to a prolonged and costly approval pathway. According to EFPIA's 2024 Key Data, an average of 12-13 years elapses from the first synthesis of a new active substance until it reaches the market. This extended timeline delays the commercialization of products and the generation of revenue, thereby diminishing the attractiveness of investing in molecular pharming initiatives. The uncertainty and high capital expenditure linked to navigating these demanding regulatory environments make it more difficult for companies to secure funding and allocate resources to the development of pharming-derived therapeutics, consequently hampering overall market growth.

Key Market Trends

The Global Molecular Pharming Market is experiencing a notable shift due to the diversification of its applications into nutraceutical production. This trend highlights the expansion of molecular pharming beyond traditional pharmaceutical proteins into generating high-value compounds for the functional food and dietary supplement industries. The inherent scalability and cost-effectiveness of molecular pharming platforms, particularly plant-based systems, are well-suited for producing vitamins, antioxidants, and other health-promoting substances, addressing a rising consumer demand for natural and bio-enhanced products. According to the Council for Responsible Nutrition, in 2024, 75% of Americans continued to use dietary supplements, demonstrating sustained consumer interest. This consistent demand propels molecular pharming companies to explore new revenue streams. For instance, Moolec Science, specializing in plant-based animal protein manufacturing via molecular pharming, secured $30 million from investors in October 2023, signaling significant investment in this diversified application.

Concurrently, a growing focus on pandemic preparedness and rapid response is a critical trend influencing the molecular pharming market. This trend underscores the technology's vital role in developing swift and scalable solutions for global health crises. Molecular pharming's capability for rapid development and production of vaccines, antiviral proteins, and diagnostic reagents is crucial for addressing emerging pathogens. This emphasis stems from lessons learned from recent global health crises, highlighting the need for agile and decentralized biomanufacturing. According to Sentinel Bio in August 2025, the Coalition for Epidemic Preparedness Innovation (CEPI) managed a vaccine research, development, and manufacturing portfolio totaling $3.8 billion across 47 countries, demonstrating extensive efforts in this domain. Furthermore, ModeX Therapeutics received a contract valued at up to $168 million from the Biomedical Advanced Research and Development Authority (BARDA) in October 2023 to advance an antibody treatment platform, emphasizing investments in rapid therapeutic development.

Segmental Insights

The Biotechnology & Pharmaceutical Companies segment is experiencing rapid growth in the Global Molecular Pharming Market due to several compelling factors. The increasing worldwide demand for advanced biologics and therapeutic proteins drives the adoption of molecular pharming, offering a cost-effective and scalable production alternative to conventional methods. Significant investments in biopharming research, coupled with continuous advancements in genetic engineering, enable more efficient and precise product development. Furthermore, strong government support and efforts by regulatory bodies like the U. S. Food and Drug Administration and the European Medicines Agency to modernize approval processes foster a conducive environment for innovation and commercialization, addressing critical unmet medical needs.

Regional Insights

North America leads the global molecular pharming market, primarily due to its advanced biopharmaceutical industry and substantial research and development investments. The region benefits from a robust healthcare infrastructure that facilitates the commercialization of molecular pharmaceutics products. Additionally, a supportive regulatory environment, involving bodies such as the U. S. Food and Drug Administration and the U. S. Department of Agriculture for biotechnology products, fosters innovation and adoption of modern agricultural technologies. The presence of key industry players and leading research institutions further strengthens this market, driving the development and acceptance of novel plant-based therapeutic production systems. These factors collectively position North America at the forefront of the molecular pharming sector.

Recent Developments

• In October 2025, Asterix Foods, an Israeli molecular farming startup, officially emerged from its development phase, announcing it had raised $4.2 million in seed funding. The capital infusion is designated to scale up the company's production of dairy, egg, and other animal proteins. This innovative approach leverages plant cell culture and a specialized growing system, which employs reusable plastic bags to enhance efficiency. This emergence marks a significant breakthrough in the molecular pharming market, aiming to provide sustainable alternatives to traditional animal-derived products through advanced plant-based biomanufacturing.

• In September 2025, Finally Foods, a molecular farming startup, successfully secured $1.2 million in funding and established a new partnership with CBC Group. This financial injection and strategic collaboration are poised to accelerate the company's initiatives within the global molecular pharming market. Such investments underscore growing confidence in the potential of plant-based systems for producing various high-value compounds, including those for food applications. The deal is expected to support further research and development efforts, advancing the commercialization of molecular farming technologies.

• In April 2025, PlantForm Corporation, a biopharmaceutical company specializing in plant-based drug development, announced a collaboration with Baiya Phytopharm and The DABOM. This partnership is focused on the co-development and production of artificial plant-made exosomes intended for therapeutic and vaccine applications. This initiative represents a significant step forward in leveraging molecular pharming platforms for advanced biopharmaceutical manufacturing, aiming to create innovative solutions for various medical needs. The collaboration highlights the continued expansion of plant-based systems into complex biological product development.

• In April 2024, Nobell Foods, a molecular farming enterprise known for creating animal-free cheese utilizing soy-derived casein proteins, publicly announced its rebranding to Alpine Bio. Concurrently with this strategic repositioning, the company secured a new patent pertaining to its dairy protein production. This development signifies a notable advancement within the molecular pharming market, highlighting the ongoing innovation in plant-based protein technologies for the food sector and demonstrating a company's commitment to expanding its intellectual property in this specialized field.

Key Market Players

• Agrenvec S.L
• Diamante SRL
• Leaf Systems International Limited
• Medicago Inc
• Meristem Therapeutics S.A.
• Moolec Science SA
• ORF Genetics
• Pfizer, Inc.
• ProdiGene Inc
• Protalix Biotherapeutics, Inc.

Report Scope:

In this report, the Global Molecular Pharming Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Molecular Pharming Market, By Crop Source:

o   Maize

o   Barley

o   Tobacco

o   Safflower

o   Rice

o   Alfalfa

• Molecular Pharming Market, By Technology:

o   Gene Gun

o   Agroinfiltration

o   Electroporation

o   Agrobacterium-Mediated Gene Transfer

o   Others

• Molecular Pharming Market, By Application:

o   Recombinant Antibodies

o   Hormones

o   Vaccines

o   Industrial Enzymes

o   Proteins & Protein-Based Materials

o   Technical Reagents

o   Nutritional Crop Sources

o   Others

• Molecular Pharming Market, By End User:

o   Biotechnology & Pharmaceutical Companies

o   Contract Manufacturing Organizations

o   Others

• Molecular Pharming Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Molecular Pharming Market.

Available Customizations:

Global Molecular Pharming Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Molecular Pharming Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]